(NASDAQ: DNTH) Dianthus Therapeutics's forecast annual revenue growth rate of -0.85% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Dianthus Therapeutics's revenue in 2024 is $2,826,000.On average, 3 Wall Street analysts forecast DNTH's revenue for 2024 to be $73,337,553, with the lowest DNTH revenue forecast at $53,645,877, and the highest DNTH revenue forecast at $107,702,609. On average, 3 Wall Street analysts forecast DNTH's revenue for 2025 to be $76,947,205, with the lowest DNTH revenue forecast at $53,645,877, and the highest DNTH revenue forecast at $118,560,910.
In 2026, DNTH is forecast to generate $80,879,671 in revenue, with the lowest revenue forecast at $53,645,877 and the highest revenue forecast at $130,299,614.